References
- Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011;117:4190-207
- Bromberg ME. Immune thrombocytopenic purpura–the changing therapeutic landscape. N Engl J Med 2006;355:1643-5
- Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113:2386-93
- Feudjo-Tepie MA, Robinson NJ, Bennett D. Prevalence of diagnosed chronic immune thrombocytopenic purpura in the US: analysis of a large US claim database: a rebuttal. J Thromb Haemost 2008;6:711-12
- Segal JB, Power NR. Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost 2006;4:2377-83
- Gernsheimer T. Epidemiology and pathophysiology of immune thrombocytopenic purpura. Eur J Haematol Suppl 2008;69:3-8
- Saleh MN, Fisher M, Grotzinger KM. Analysis of the impact and burden of illness of adult chronic ITP in the US. Curr Med Res Opin 2009;25:2961-9
- Aledort LM, Lyons RM, Okano G, et al. The clinical and direct medical cost burden of splenectomy among managed care patients with chronic Immune Thrombocytopenic Purpura (ITP). Blood 2006;108:5536
- Danese MD, Lindquist K, Gleeson M, et al. Cost and mortality associated with hospitalizations in patients with immune thrombocytopenic purpura. Am J Hematol 2009;84:631-5
- Tarantino M, Mathias SD, Snyder CF, et al. Impact of ITP on physician visits and workplace productivity. Curr Med Res Opin 2010;26:319-28
- Neunert CE. Current management of immune thrombocytopenia. Hematol Am Soc Hematol Educ Program 2013;2013:276-82
- Bussel J, Tarantino M, Nalysnyk L, et al. Intravenous rhesus immune globulin and intravenous immunoglobulin in immune thrombocytopenic purpura. US Hematology 2007;1:28-34
- Arnold DM, Heddle NM, Carruthers J, et al. A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia. Blood 2012;119:1356-62
- Kuter DJ, Bussel JB, Newland A, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol 2013;161:411-23
- Saleh MN, Bussel JB, Cheng G, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood 2013;121:537-45
- Brown TM, Horblyuk RV, Grotzinger KM, et al. Patient-reported treatment burden of chronic immune thrombocytopenia therapies. BMC Blood Disord 2012;12:2
- Auger S, Duny Y, Rossi JF, et al. Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis. Br J Haematol 2012;158:386-98
- Romiplostim package insert. Thousand Oaks, CA, USA: Amgen Inc. Nplate® Package Insert. 2014. http://pi.amgen.com/united_states/nplate/nplate_pi_hcp_english.pdf
- Eltrombopag package insert. Research Triangle Park, NC, USA: GlaxoSmithKline. Promacta Package Insert. 2014. https://www.gsksource.com/gskprm/htdocs/documents/PROMACTA.PDF
- Anti-D package insert. Winnipeg, Manitoba, Canada: Emergent BioSolutions Inc. WinRho® SDF Package Insert. 2014. http://www.winrho.com/pdfs/WinRho_PI.pdf
- IVIG package insert. Bern, Switzerland: CSL Behring. PrivigenTM Package Insert. 2014. http://labeling.cslbehring.com/PI/US/Privigen/EN/Privigen-Prescribing-Information.pdf
- Rituximab package insert. South San Francisco, CA, USA: Genentech, Inc. Rituxan® Package Insert. 2014. http://www.gene.com/download/pdf/rituxan_prescribing.pdf
- Quan H, Li B, Couris CM, et al. Updating and validating the Charlson Comorbidity Index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 2011;173:676-82
- Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
- Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
- Hanley JA, Negassa A, Edwardes MD, et al. Statistical analysis of correlated data using generalized estimating equations: an orientation. Am J Epidemiol 2003;157:364-75
- Food and Drug Administration. Risk Evaluation and Mitigation Strategy (REMS) BL 125268 Nplate® (romiplostim). August 2008. Thousand Oaks, CA, USA: Amgen Inc. http://www.fda.gov/downloads/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm129516.pdf
- Food and Drug Administration. Risk Evaluation and Mitigation Strategy (REMS) NDA 22-291 PROMACTA® (eltrombopag). November 2008. Collegeville, PA, USA: GlaxoSmithKline. http://www.fda.gov/downloads/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm144246.pdf
- Sandler SG, Novak SC, Roland B. Cost of treating immune thrombocytopenic purupra using intravenous Rh immune globulin versus intravenous immune globulin. Am J Hematol 2000;63:156-8
- Bennett CL. Comparison of the efficacy, safety, and cost of agents used to treat idiopathic thrombocytopenic purpura in adults and children. Pharm Pract News. 2007. New York, NY, USAhttp://www.pharmacypracticenews.com/download/sr07046wm.pdf
- Ghanima W, Godeau B, Cines DB, et al. How I treat immune thrombocytopenia (ITP): the choice between splenectomy or a medical therapy as a second-line treatment. Blood 2012;120:960-9